Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Extending levodopa action: COMT inhibition

P Martínez-Martín1, C F O'Brien

  • 1Department of Neurology, Hospital Universitario de Getafe, Madrid, Spain.

Neurology
|June 20, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An international 20 country patient and physician survey of the usability and acceptability of Stepped Care pathway in Parkinson's disease.

Scientific reports·2025
Same author

Staging Parkinson's Disease Combining Motor and Nonmotor Symptoms Correlates with Disability and Quality of Life.

Parkinson's disease·2021
Same author

[Pilot study of a new tool to optimise dopaminergic treatment in Parkinson's disease: the OPTIMIPARK questionnaire].

Revista de neurologia·2021
Same author

Sleep Problems Are Related to a Worse Quality of Life and a Greater Non-Motor Symptoms Burden in Parkinson's Disease.

Journal of geriatric psychiatry and neurology·2020
Same author

Non-motor symptom burden in patients with Parkinson's disease with impulse control disorders and compulsive behaviours: results from the COPPADIS cohort.

Scientific reports·2020
Same author

Quality of life and non-motor symptoms in Parkinson's disease patients with subthreshold depression.

Journal of the neurological sciences·2020
Same journal

Phenotype, Severity, and Therapy of Patients With LRP4 Antibody-Associated Myasthenia Gravis in the German Myasthenia Gravis Registry.

Neurology·2026
Same journal

Association of Changes in Intrinsic Capacity With Cognitive Decline and Dementia: A Prospective Cohort Study.

Neurology·2026
Same journal

Role of the Upper Motor Neuron in the Generation of Fasciculations in Early Disease Stages of Amyotrophic Lateral Sclerosis.

Neurology·2026
Same journal

Factors Associated With Disability Improvement and Worsening Independent of Attacks in Patients With AQP4-IgG+ NMOSD and MOGAD: A Multicenter Cohort Study.

Neurology·2026
Same journal

Cost-Effectiveness of Intracranial Aneurysm Screening: A Systematic Review.

Neurology·2026
Same journal

Rare Eating Epilepsy: Co-Occurrence of Focal Cortical Dysplasia and Gray Matter Heterotopia.

Neurology·2026
See all related articles

Catechol-O-methyltransferase (COMT) inhibitors help Parkinson's disease patients by extending levodopa's effectiveness and reducing motor fluctuations. This approach can decrease the required levodopa dose, potentially managing dyskinesia.

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • Levodopa is a primary treatment for Parkinson's disease (PD).
  • Peripheral degradation of levodopa by catechol-O-methyltransferase (COMT) contributes to motor fluctuations and dyskinesia in PD patients.
  • Inhibiting COMT is a strategy to enhance levodopa's therapeutic effect.

Purpose of the Study:

  • To review the role of COMT inhibitors in managing Parkinson's disease.
  • To discuss the efficacy and side effects of new nitrocatechol-type COMT inhibitors.

Main Methods:

  • Review of existing literature on COMT inhibitors and their clinical impact.
  • Analysis of the pharmacokinetic and pharmacodynamic properties of entacapone, nitecapone, and tolcapone.

Main Results:

Related Experiment Videos

  • COMT inhibitors, including entacapone, nitecapone, and tolcapone, effectively extend levodopa's duration of action.
  • These inhibitors reduce motor response fluctuations in Parkinson's disease patients.
  • Tolcapone exhibits both peripheral and central COMT inhibition.
  • While levodopa-induced dyskinesia may be prolonged, peak-dose dyskinesia is not increased, allowing for potential reduction in total daily levodopa dosage.

Conclusions:

  • COMT inhibitors are valuable adjuncts in Parkinson's disease therapy.
  • They improve motor control and reduce fluctuations by increasing levodopa bioavailability.
  • Careful dosage adjustment of levodopa may be necessary to manage potential side effects like dyskinesia.